NICE(NICE)

Search documents
Nice (NICE) Beats Stock Market Upswing: What Investors Need to Know
ZACKS· 2025-01-22 00:05
In the latest trading session, Nice (NICE) closed at $165.52, marking a +1.92% move from the previous day. This move outpaced the S&P 500's daily gain of 0.88%. Meanwhile, the Dow gained 1.24%, and the Nasdaq, a tech-heavy index, added 0.65%.The the stock of software company has fallen by 6.49% in the past month, lagging the Computer and Technology sector's gain of 0.37% and the S&P 500's gain of 1.17%.The investment community will be paying close attention to the earnings performance of Nice in its upcomin ...
NICE vs. PYCR: Which Stock Should Value Investors Buy Now?
ZACKS· 2025-01-15 17:41
Investors interested in stocks from the Internet - Software sector have probably already heard of Nice (NICE) and Paycor HCM, Inc. (PYCR) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets c ...
Should You Hold NICE Stock Despite 20% Decline Over the Past Year?
ZACKS· 2025-01-14 19:36
Company Performance and Financials - NICE launched CXone Mpower, an AI-driven platform to enhance customer service automation and engagement, tailored to customer needs [1] - The company secured over 100 large enterprise accounts year-to-date, displacing legacy competitors and attracting 45 leading brands after failed deployments from other cloud vendors [2] - For Q1 fiscal 2025, the Zacks Consensus Estimate for earnings is $2 90 per share, indicating a 12 4% YoY growth, while revenue is estimated at $721 31 million, a 9 4% increase from the prior-year quarter [3] - NICE shares have fallen 20 4% over the past year, underperforming the Zacks Computer & Technology sector (29 3%) and the Zacks Internet – Software industry (30 6%) [4] - The company's earnings have beaten the Zacks Consensus Estimate in the trailing four quarters, with an average surprise of 4 88% [3] Market Position and Competition - NICE faces stiff competition in the Customer Engagement and Financial Crime and Compliance segments, competing with companies like Aspect, Calabrio, Genesys, and Verint Systems in Workforce Optimization [7] - In the Contact Center as a Service market, NICE competes with key players such as Avaya, Cisco Systems, Five9, and TalkDesk, alongside niche vendors [8] - The company leads in AI-driven solutions for customer experiences, financial crime, and digital policing transformation, monitoring 5 billion transactions daily and safeguarding $6 trillion [13] - NICE serves the top 10 global banks and has a projected Total Addressable Market (TAM) of $5 billion by 2028, driven by advancements in its X-Sight platform and cloud solutions [13] Growth Drivers and Challenges - NICE has expanded its partner ecosystem by adding over 40 partners, including 20 international partners, which is expected to drive growth [2] - The company's presence in over 150 countries and engagement with more than 85% of Fortune 100 customers provides a solid foundation for international expansion [10] - Despite challenges, NICE is expected to benefit from growth in the cloud business and AI domain, driven by platform innovation and a growing client base [6] - The adoption of AI solutions like Autopilot, CSAT, and Copilot has significantly boosted NICE's performance by enhancing customer engagement and automating services [9] - The company's negative share price movement is attributed to declining service revenue due to the transition to cloud-based services and volatility in product revenues [5] Industry and Market Trends - NICE's Financial Crime and Compliance market solutions, such as X-Sight and Xceed, help financial organizations manage risks, prevent fraud, and ensure compliance in real-time [12] - Key competitors in the Financial Crime and Compliance space include BAE Systems, FICO, NASDAQ Smarts, Oracle, and SAS Institute, offering specialized and comprehensive solutions [12]
Nice (NICE) Stock Falls Amid Market Uptick: What Investors Need to Know
ZACKS· 2025-01-09 23:55
In the latest market close, Nice (NICE) reached $165.72, with a -0.37% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 0.16% for the day. Elsewhere, the Dow gained 0.25%, while the tech-heavy Nasdaq lost 0.06%.Heading into today, shares of the software company had lost 9.55% over the past month, lagging the Computer and Technology sector's loss of 0.39% and the S&P 500's loss of 2.7% in that time.The upcoming earnings release of Nice will be of great in ...
Is Nice (NICE) a Buy as Wall Street Analysts Look Optimistic?
ZACKS· 2024-12-19 15:30
Core Viewpoint - The article discusses the reliability of Wall Street analysts' recommendations, particularly focusing on Nice (NICE), and suggests that while the average brokerage recommendation (ABR) indicates a positive outlook, it may not be a reliable basis for investment decisions [1][4]. Group 1: Brokerage Recommendations - Nice has an average brokerage recommendation (ABR) of 1.33, indicating a position between Strong Buy and Buy, based on recommendations from 15 brokerage firms [2]. - Out of the 15 recommendations, 12 are Strong Buy and 1 is Buy, which accounts for 80% and 6.7% of all recommendations respectively [2]. Group 2: Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations often fail to guide investors effectively towards stocks with high potential for price appreciation [4]. - The vested interests of brokerage firms can lead to a bias in analysts' ratings, with a ratio of five "Strong Buy" recommendations for every "Strong Sell" [5][9]. - This misalignment of interests suggests that brokerage recommendations may mislead investors rather than provide accurate insights into stock price movements [6][9]. Group 3: Zacks Rank as an Alternative - Zacks Rank, a proprietary stock rating tool, categorizes stocks into five groups and is based on earnings estimate revisions, making it a more effective indicator of near-term stock performance [7][10]. - Unlike ABR, which is based solely on brokerage recommendations, Zacks Rank is updated frequently to reflect changes in earnings estimates, providing timely predictions for stock prices [11]. - For Nice, the Zacks Consensus Estimate for the current year remains unchanged at $11.05, leading to a Zacks Rank of 3 (Hold), suggesting caution despite the positive ABR [12][13].
NICE Gains 11% in 3 Months: Should You Buy, Sell or Hold the Stock?
ZACKS· 2024-12-11 18:35
NICE’s (NICE) shares have gained 10.9% over the past three months, outperforming the Zacks Computer & Technology sector’s return of 10.2%.The rise in share price can be attributed to robust growth in the cloud business, which accounted for 72.5% of total revenues and saw 24% year-over-year growth in the third quarter of 2024. The widespread adoption of AI solutions, including the successful launch of products such as Autopilot and Copilot, coupled with significant wins in major enterprise deals, played an i ...
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
GlobeNewswire News Room· 2024-12-04 13:05
Core Insights - The article highlights the first positive reimbursement decision for LYTENAVA™ (bevacizumab gamma) by NICE, marking a significant milestone for Outlook Therapeutics in the treatment of wet AMD [1][2][4] Company Overview - Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing LYTENAVA™ for retinal diseases, particularly wet AMD [9] - LYTENAVA™ is the first ophthalmic formulation of bevacizumab approved in the EU and UK for treating wet AMD, with an initial 10 years of market exclusivity [1][9] Regulatory Approval and Market Launch - NICE has recommended LYTENAVA™ as a treatment option for wet AMD, applicable in England and Wales, following its marketing authorization by the UK Medicines and Healthcare products Regulatory Agency (MHRA) [2][3] - The commercial launch of LYTENAVA™ in the UK is anticipated in the first half of 2025, with plans for subsequent launches in EU countries [2][9] Clinical Evidence - The NICE recommendation was based on results from three completed registration clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE, along with supporting studies [4] Strategic Collaborations - Outlook Therapeutics has entered a strategic collaboration with Cencora to support the global commercial launch of LYTENAVA™, focusing on market access and distribution efficiency [5]
Nice Is An Excellent AI Opportunity In Client Management Software
Seeking Alpha· 2024-12-03 12:42
Core Insights - Nice Ltd (NASDAQ: NICE) has experienced a decline of 5% over the past year, contrasting sharply with a 32% gain in the S&P 500 index [1] Company Performance - The performance of Nice Ltd has been underwhelming compared to broader market indices, indicating potential challenges or market sentiment issues affecting the company [1] Analyst Perspective - The article reflects a long position in Nice Ltd, suggesting a belief in the company's potential despite recent performance [2]
Can NICE's WFM Solution Boost Maxicare's CX and Push the Stock Higher?
ZACKS· 2024-11-27 17:26
Core Insights - NICE has enhanced its contact center operations through a partnership with Maxicare, improving customer experience and agent empowerment [1] - The implementation of NICE's Workforce Management (WFM) has led to significant improvements in key performance metrics for Maxicare [2][3] - NICE's cloud revenues have shown substantial growth, reflecting the increasing demand for cloud-native solutions [4] Group 1: Operational Enhancements - Maxicare has utilized NICE WFM to improve average handle time, response time, and call abandonment rates [2] - The collaboration has resulted in a 90% customer satisfaction rate for Maxicare, with plans for further service quality enhancements [3] Group 2: Product Portfolio and Revenue Growth - NICE's diverse product portfolio, including solutions like Actimize and CXone, has contributed to a 24% year-over-year increase in cloud revenues, reaching $500 million in Q3 2024 [4] - The successful implementation of NICE CXone by AUSIEX has led to a 33% increase in customer engagement [5] Group 3: Strategic Partnerships - NICE's partnerships with AT&T and Microsoft have been pivotal in attracting new customers and expanding its market presence [7][8] - The collaboration with AT&T focuses on providing a unified incident capture and data analytics solution for NextGen 9-1-1 centers [7] Group 4: Financial Estimates - The Zacks Consensus Estimate for NICE's Q4 2024 revenues is $713.01 million, indicating a 14.41% year-over-year growth [9] - The consensus estimate for earnings per share is $2.96, reflecting a 25.42% year-over-year increase [9] Group 5: Competitive Landscape - NICE faces challenges from stiff competition and foreign exchange headwinds in the APAC market, impacting its top-line growth [11] - Competitors like Five9 and Salesforce are enhancing their portfolios in the customer experience market, posing additional challenges for NICE [12]
Here's Why Nice (NICE) is a Strong Value Stock
ZACKS· 2024-11-22 15:45
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? Dev ...